📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-28 16:13
570 analysed today
570
Today
133,459
All-time analysed
40,112
Positive
6,281
Negative
79,251
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
34 announcements match the current filters (relevance ≥ 5).
Krsnaa Diagnostics: Corrigendum on 16.21 Lakh Promoter Warrants; Stake to Rise to 29.70%
Krsnaa Diagnostics issued a corrigendum to its Postal Ballot Notice following directives from the NSE regarding its proposed preferential issue of share warrants. Under the proposal, 16,21,000 warrants will be allotted to promoter entities, including Mr. Rajendra Khivraj Mutha (75,000) and Krsna Diagnostics (Mumbai) Pvt Ltd (15,46,000). Upon full warrant exercise and ESOP dilution, the promoter and promoter group holding will increase from 27.11% to 29.70% across an expanded base of 3,50,65,279 shares. The e-voting process for shareholder approval is open until September 17, 2026.
Confidence: HIGH
What changedProvided expanded disclosures on promoter allottees, beneficial ownership, and post-issue capital structure per NSE review.
Why it mattersIncreases promoter commitment and equity ownership from 27.11% to 29.70%, injecting fresh equity capital into the company.
Warrants proposed: 16,21,000Pre-issue promoter holding: 27.11%Post-issue promoter holding: 29.70%Post-issue share count (fully diluted): 3,50,65,279E-voting end date: September 17, 2026
📅 Short termEnsures regulatory compliance ahead of the postal ballot closure on September 17, 2026, with minimal short-term price impact.
📈 Long termStrengthens capital structure and aligns promoter incentives through higher equity ownership without triggering open offer obligations.
⚠ Risk flags
- Minor equity dilution of non-promoter shareholding from 72.89% to 70.30%.
Key Highlights
Proposed preferential issue of 16,21,000 share warrants to promoter group entities.
Promoter holding set to increase from 27.11% (87,95,605 shares) to 29.70% (1,04,16,605 shares) on a fully diluted basis.
Allotment split: 75,000 warrants to Mr. Rajendra Khivraj Mutha and 15,46,000 warrants to Krsna Diagnostics (Mumbai) Private Limited.
Remote e-voting window closes at 5:00 PM IST on September 17, 2026.
👀 What to Watch
Track the shareholder voting results on September 17, 2026, and watch for final regulatory approvals and warrant exercise pricing details.
Krsnaa Diagnostics receives additional Income Tax demand of ₹12.10 Cr for AY 2022-23
Krsnaa Diagnostics received a rectification order under Section 154 read with Section 143(3) of the Income Tax Act, 1961 for AY 2022-23 from the ACIT, Pune. The order recomputes tax under Section 115BBE, raising the total balance payable from ₹19.63 Cr to ₹31.73 Cr, creating an additional demand of ₹12.10 Cr (~12.3% of TTM PAT). Total assessed income remains unchanged at ₹98.27 Cr. The company plans to file an appeal and rectification against the additional demand, having already contested the original assessment.
Confidence: HIGH
What changedIncome Tax Department issued a rectification order increasing the tax demand for AY 2022-23 by ₹12.10 Cr due to the application of Section 115BBE tax rates.
Why it mattersThe revised total demand of ₹31.73 Cr represents ~32.4% of TTM PAT (₹98 Cr), posing a potential financial liability if appellate proceedings are unfavorable.
Additional tax demand: ₹12,09,98,110Revised total tax payable: ₹31,73,28,734Total assessed income: ₹98,27,29,935Additional demand vs TTM PAT: ~12.3%Total revised demand vs TTM PAT: ~32.4%
📅 Short termNegative sentiment due to the unexpected tax liability; however, an appeal will defer immediate cash outflows pending appellate review.
📈 Long termLimited operational impact, though adverse resolution could lead to cash outflow and write-offs impacting net profit.
⚠ Risk flags
- Adverse tax dispute outcome leading to cash outflow of up to ₹31.73 Cr
- Potential for interest/penalty accruals pending final appellate resolution
Key Highlights
Additional tax demand of ₹12,09,98,110/- raised for Assessment Year 2022-23
Revised balance tax payable stands at ₹31,73,28,734/- vs ₹19,63,30,624/- earlier
Total assessed income remains unchanged at ₹98,27,29,935/-
Tax rate rectified to 60% plus 25% surcharge under Section 115BBE on additions under Sections 69A and 69C
Company is in the process of filing an appeal/rectification against the order
👀 What to Watch
Track the outcomes of the appeal filed before the appellate authority and any potential cash flow impact or tax provisioning in upcoming quarterly results.
Krsnaa Diagnostics to raise ₹91.75 Cr via preferential issue of warrants at ₹566/share
Krsnaa Diagnostics has announced the terms of a preferential issue of up to 16,21,000 convertible warrants at an issue price of ₹566 per warrant, aggregating to ₹91.75 crore. The warrants are proposed to be allotted to Mr. Rajendra Mutha (75,000 warrants for ₹4.25 crore) and Krsnaa Diagnostics (Mumbai) Private Limited (15,46,000 warrants for ₹87.50 crore). Each warrant is convertible into one equity share within an 18-month period. The total fundraise represents approximately 5.2% of the company's market capitalisation (₹1,757 crore) and comes at a premium to the current market price of ₹540.30.
Confidence: HIGH
What changedFormal disclosure of preferential warrant allotment terms, issue price (₹566), and investor allocation totaling ₹91.75 crore.
Why it mattersDemonstrates promoter capital commitment at a premium to current market price, infusing growth capital and strengthening the balance sheet.
Total fundraise amount: Rs. 91,74,86,000Fundraise vs Market cap: ~5.2%Issue price per warrant: INR 566Total warrants: 16,21,000Conversion window: 18 months
📅 Short termPositive sentiment likely due to insider participation at an issue price above the current market price of ₹540.30.
📈 Long termProvides equity funding to support ongoing PPP projects and retail expansion without increasing long-term debt leverage.
⚠ Risk flags
- Dilution to minority shareholders upon full conversion
- Dependency on full warrant conversion within 18 months for complete cash inflow
Key Highlights
Preferential issuance of up to 16,21,000 warrants aggregating to ₹91.75 crore.
Issue price fixed at ₹566 per warrant in accordance with SEBI ICDR Regulations as of August 18, 2026.
Krsnaa Diagnostics (Mumbai) Pvt Ltd to subscribe to 15,46,000 warrants, increasing stake from 2.36% to 6.78%.
Mr. Rajendra Mutha to subscribe to 75,000 warrants (post-allotment shareholding will be 23.79%).
Warrants have a conversion tenure of up to 18 months from allotment.
👀 What to Watch
Track shareholder/EGM approval outcome, receipt of the initial 25% warrant subscription amount, and clarity on end-use of proceeds towards capex/debt reduction in upcoming quarterly briefings.
Krsnaa Diagnostics seeks shareholder nod for Rs 91.75 Cr warrant issue to promoters at Rs 566/share
Krsnaa Diagnostics has issued a postal ballot notice seeking shareholder approval to issue up to 16,21,000 convertible warrants on a preferential basis to its Promoter and Promoter Group. The warrants are priced at Rs 566 per share (face value Rs 5 + Rs 561 premium), raising up to Rs 91.75 Cr, which represents ~5.1% of its current market cap of Rs 1,792 Cr. The issue price is slightly above the current market price of Rs 551. Remote e-voting is scheduled from August 19, 2026, to September 17, 2026.
Confidence: HIGH
What changedThe company formally initiated postal ballot proceedings to approve a preferential issue of 16.21 lakh convertible warrants to the promoter group at Rs 566 per warrant.
Why it mattersDemonstrates promoter commitment by injecting up to Rs 91.75 Cr in equity capital at a price above prevailing market rates, potentially raising promoter holding from the current 27.11% and supporting ongoing PPP expansion capex.
Total fundraise value: Rs 91,74,86,000Warrants offered: 16,21,000Issue price per warrant: Rs 566Fundraise vs Market cap: ~5.1%E-voting cut-off date: August 14, 2026
📅 Short termLikely to support market sentiment in the near term as promoters are infusing capital at Rs 566 per share, above current trading levels.
📈 Long termProvides long-term equity capital to strengthen the balance sheet (current debt Rs 531 Cr) and support expansion into new state PPP contracts and retail diagnostics.
⚠ Risk flags
- Equity dilution of ~4.8% on fully diluted equity base upon warrant conversion
- Warrant funds are received in tranches (25% upfront, 75% over up to 18 months)
Key Highlights
Preferential issuance of up to 16,21,000 convertible warrants to Promoter and Promoter Group
Issue price fixed at Rs 566 per warrant (Rs 5 face value plus Rs 561 premium)
Total fundraising size of up to Rs 91.75 Cr (~5.1% of market cap)
Remote e-voting window open from August 19, 2026 to September 17, 2026
👀 What to Watch
Track shareholder voting results after September 17, 2026, followed by stock exchange in-principle approvals and receipt of the mandatory upfront 25% warrant subscription amount.
22% Revenue Growth in Q1 FY27; Retail Segment Surges 64% YoY to Rs 19.3 Cr
Krsnaa Diagnostics reported a 22% YoY revenue growth to Rs 235.5 Cr for Q1 FY27, driven by the ramp-up of the Rajasthan contract and strong retail performance. However, PAT declined 19% YoY to Rs 16.6 Cr, and EBITDA margins contracted by 221 bps to 25% due to upfront fixed costs in Rajasthan. The retail segment showed significant momentum, with its revenue contribution rising to 8% of the total, up from 1% in the previous year. The company maintains a robust order book with over 200 CT/MRI centers planned for completion.
Confidence: HIGH
What changedThe company is transitioning from a purely PPP-driven model to a hybrid model with an increasing retail footprint (8% of revenue) and is currently absorbing high upfront costs for its Rajasthan expansion.
Why it mattersWhile top-line growth remains strong, the temporary margin compression and PAT decline reflect the execution risks of large-scale government contracts. The shift toward retail is critical for long-term margin stability and reducing receivable risks.
Q1 FY27 Revenue: Rs 235.5 CrQ1 Revenue vs TTM Revenue: 30.4%Retail Revenue Growth: 64%EBITDA Margin: 25%Q1 FY27 PAT: Rs 16.6 Cr
📅 Short termThe stock may face pressure due to the 19% YoY decline in PAT and margin contraction, despite healthy revenue growth.
📈 Long termThe structural shift toward a 20% retail revenue target by FY27 and the scale-up of the Rajasthan contract are positive long-term drivers if margins normalize.
⚠ Risk flags
- Margin compression from upfront expansion costs
- Stretched receivables from government entities
- High client concentration in government health departments
Key Highlights
Revenue from operations grew 22% YoY to Rs 235.5 Cr in Q1 FY27.
Retail revenue surged 64% YoY to Rs 19.3 Cr, now contributing 8% of total revenue.
PAT decreased 19% YoY to Rs 16.6 Cr from Rs 20.5 Cr in the year-ago period.
EBITDA margins compressed to 25% from 27% due to upfront costs for Rajasthan laboratories.
Radiology network expanded to 191 CT/MRI centers with a total of 120 accreditations (NABL + NABH).
👀 What to Watch
Monitor the utilization levels and margin recovery in the Rajasthan project over the next two quarters. Watch for the company's ability to maintain retail growth momentum and improve cash conversion from government contracts.
22% Revenue Growth in Q1 FY27; Rajasthan Project Goes Live; Promoter Warrant Issue Approved
Krsnaa Diagnostics reported a 22% YoY revenue growth to ₹235.5 Cr for Q1 FY27, primarily driven by the operationalization of the Rajasthan pathology network. The Rajasthan project contributed ₹25.7 Cr (approx. 11% of quarterly revenue) with 1,321 units now operational. However, PAT declined 19% YoY to ₹16.6 Cr as EBITDA margins contracted from 27% to 25% due to upfront fixed costs of new infrastructure. The Board also approved a preferential warrant issue to promoters, signaling internal backing as the company scales its retail and PPP segments.
Confidence: HIGH
What changedThe massive Rajasthan pathology contract has transitioned from the implementation phase to active operations, and the company has initiated a fundraise from promoters via share warrants.
Why it mattersRajasthan is a critical growth engine for Krsnaa; its successful scale-up is vital for hitting FY27 targets. The promoter warrant issue provides capital for expansion while signaling management's commitment despite recent margin pressure.
Q1 Revenue: ₹235.5 CrRajasthan Revenue Contribution: ₹25.7 CrQ1 Revenue vs TTM Revenue: 30.5%Retail Revenue Growth: 64% YoYEBITDA Margin: 25%
📅 Short termThe stock may face pressure due to the YoY decline in PAT and margin contraction, though the strong top-line growth and Rajasthan operationalization provide a fundamental floor.
📈 Long termThe structural expansion into Rajasthan and the growth of the high-margin retail segment (targeting 20% of revenue by FY27) could significantly re-rate the business as fixed costs are absorbed by higher volumes.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin compression due to high upfront fixed costs
- Dilution risk from the upcoming preferential warrant issue
- High dependency on government (PPP) contracts and associated receivable risks
Key Highlights
Revenue from operations increased 22% YoY to ₹235.5 Cr, with like-for-like projects growing 12%.
Rajasthan pathology network is now live with 31 mother labs, 62 hub labs, and 1,228 collection centers.
Retail segment revenue grew 64% YoY to ₹19.3 Cr, now reaching over 4,250 touchpoints.
PAT decreased to ₹16.6 Cr from ₹20.5 Cr YoY, reflecting a margin drop to 7% from 11%.
Secured a new project award in Himachal Pradesh for the installation of 34 CT scanners.
👀 What to Watch
Monitor the utilization ramp-up in the Rajasthan and Maharashtra projects over the next two quarters to see if operating leverage restores PAT margins to the 10-12% range. Investors should also watch for the specific pricing and size of the promoter warrant issue once detailed terms are disclosed.
Krsnaa Q1 Revenue up 22% to ₹235.5 Cr; Promoter to Infuse Capital via Warrants at ₹565
Krsnaa Diagnostics reported a 22% YoY revenue growth in Q1 FY27 to ₹235.53 Cr, driven by its expanding PPP footprint. However, Net Profit (PAT) declined by 19.3% YoY to ₹16.55 Cr, impacted by higher finance costs and hospital fees. The board approved a preferential issuance of 16.21 lakh warrants to promoters at ₹565 per share (a premium to the current market price), potentially raising ~₹91.6 Cr. A significant monitorable remains the ₹62.69 Cr income tax demand currently under appeal, which represents over 60% of the company's TTM PAT.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and announced a fresh capital infusion from promoters via warrants at a premium to the current market price.
Why it mattersThe revenue growth confirms the company's ability to win and execute large government tenders, but the PAT decline and tax litigation highlight operational and regulatory risks.
Q1 Revenue: ₹235.53 CrQ1 PAT: ₹16.55 CrWarrant Issue Price: ₹565Tax Demand vs TTM PAT: 61.6%Dividend per share: ₹2.00
📅 Short termThe stock may face pressure due to the YoY decline in PAT and the large tax demand, though the promoter warrant pricing at ₹565 may provide a psychological floor.
📈 Long termLong-term value depends on the company's ability to transition its revenue mix toward 20% retail by FY27 and resolve stretched receivables in states like Himachal Pradesh and Karnataka.
⚠ Risk flags
- Material income tax demand of ₹62.69 Cr
- Stretched receivables from government health departments
- Margin compression in the current quarter
Key Highlights
Revenue from operations increased 22% YoY to ₹235.53 Cr in Q1 FY27.
Net Profit (PAT) fell to ₹16.55 Cr from ₹20.52 Cr in the same quarter last year.
Promoter warrant issuance of 16.21 lakh units at a minimum price of ₹565, representing a ~5.1% value of current market cap.
Income tax demand of ₹62.69 Cr is being contested; ₹3.93 Cr deposited under protest.
Final dividend of ₹2.00 per share confirmed with a record date of September 18, 2026.
👀 What to Watch
Monitor the scale-up of the Rajasthan and Maharashtra contracts to see if margins recover from the current 24.6% level. Investors should also track the progress of the income tax appeals as the demand is material relative to annual profits.
KRSNAA Q1 Revenue Up 22% to ₹235.5 Cr; Board Approves ₹91.6 Cr Warrant Issue to Promoters
Krsnaa Diagnostics reported a 22% YoY increase in Q1 FY27 consolidated revenue to ₹235.53 Cr, though net profit declined to ₹16.55 Cr from ₹20.52 Cr due to higher finance and operational costs. The board approved a preferential issue of 16.21 lakh warrants to promoters at a minimum price of ₹565, signaling a potential capital infusion of ~₹91.6 Cr (approx. 5% of market cap). A final dividend of ₹2.00 per share was confirmed with a record date of September 18, 2026. Investors should note an ongoing income tax dispute involving a demand of ₹62.69 Cr, which the company is currently appealing.
Confidence: HIGH
What changedThe company has transitioned from FY26 results to Q1 FY27 reporting, initiated a promoter-led fundraise via warrants, and finalized the dividend timeline.
Why it mattersThe warrant issue provides growth capital and reinforces promoter commitment, while the mixed earnings reflect the challenge of maintaining margins amidst rising finance costs and government-linked receivables.
Q1 FY27 Revenue: ₹235.53 CrQ1 FY27 Net Profit: ₹16.55 CrWarrant Issue Value (est): ₹91.59 CrWarrant Issue vs Market Cap: ~5.1%Tax Demand under Appeal: ₹62.69 CrDividend per Share: ₹2.00
📅 Short termThe stock may face pressure due to the YoY profit decline, though the promoter warrant issue at ₹565 (near current market price) provides a psychological support level.
📈 Long termGrowth depends on scaling the retail segment from 8% to 20% of revenue and successfully operationalizing large PPP contracts in Rajasthan and Maharashtra.
⚠ Risk flags
- Significant income tax demand of ₹62.69 Cr
- Stretched receivables from government entities in Himachal Pradesh and Karnataka
- Rising finance costs impacting net margins
Key Highlights
Consolidated Revenue for Q1 FY27 rose 22.05% YoY to ₹235.53 Cr from ₹192.98 Cr
Net Profit for the quarter fell 19.3% YoY to ₹16.55 Cr, impacted by finance costs rising to ₹14.83 Cr
Preferential issue of 16,21,000 warrants to promoters at ₹565 or floor price, totaling ~₹91.6 Cr
Final dividend of ₹2.00 per share declared for FY25 with Record Date set for Sept 18, 2026
Income tax demand of ₹62.69 Cr under appeal; management views the demand as not tenable
👀 What to Watch
Monitor the conversion of warrants into equity over the next 18 months and the progress of the ₹62.69 Cr tax appeal, which represents ~6% of the company's net worth.
Q1 Revenue Up 22% to ₹235 Cr; Promoters to Inject Capital via 16.21 Lakh Warrants at ₹565
Krsnaa Diagnostics reported a strong 22% YoY revenue growth in Q1 FY27, reaching ₹235.5 cr, driven by its expanding PPP footprint. However, Net Profit declined 19% YoY to ₹16.55 cr, primarily due to finance costs doubling to ₹14.83 cr and increased depreciation. The board approved a preferential issuance of 16.21 lakh warrants to promoters at a minimum price of ₹565, representing a ~5% potential equity dilution. Additionally, the company is contesting a significant ₹62.69 cr income tax demand resulting from past search operations.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial performance and announced a promoter-led capital infusion through share warrants at a premium to the current market price.
Why it mattersWhile top-line growth remains robust due to government contracts, the bottom-line is under pressure from higher interest and depreciation costs. The promoter warrant subscription signals long-term confidence but will lead to equity dilution.
Revenue (Q1 FY27): ₹235.53 crPAT (Q1 FY27): ₹16.55 crWarrant Issue Price: ₹565Tax Demand Under Dispute: ₹62.69 crFinance Costs (Q1 FY27): ₹14.83 crWarrant Dilution (Approx): 5%
📅 Short termThe market may react cautiously to the PAT decline and the large tax demand, though the promoter warrant pricing at ₹565 provides a psychological floor.
📈 Long termStructural growth depends on the successful operationalization of large state-level contracts and the ability to scale the retail segment to 20% of revenue by FY27.
⚠ Risk flags
- Margin compression due to rising finance and depreciation costs
- Significant tax litigation risk (₹62.69 cr)
- Equity dilution from warrant conversion
- High receivables concentration in government segments
Key Highlights
Revenue from operations grew 22.1% YoY to ₹235.53 cr in Q1 FY27 from ₹192.98 cr.
Net Profit fell 19.3% YoY to ₹16.55 cr, with EPS dropping to ₹5.10 from ₹6.35.
Promoters to subscribe to 16.21 lakh warrants at ₹565 or higher, a premium to the current price of ₹556.8.
Income tax demand of ₹62.69 cr is under appeal; ₹3.93 cr already deposited under protest.
Final dividend of ₹2.00 per share for FY25 confirmed with a record date of September 18, 2026.
👀 What to Watch
Monitor the impact of rising finance costs on net margins and the progress of the ₹62.69 cr tax litigation. Investors should also track the utilization of the warrant proceeds for the planned expansion in Rajasthan and Maharashtra.
KRSNAA Q1 Revenue Up 22% to ₹235.5 Cr; Board Approves ₹91.6 Cr+ Promoter Warrant Issue
Krsnaa Diagnostics reported a mixed Q1 FY27 with revenue growing 22% YoY to ₹235.5 cr, driven by operationalizing new centers. However, Net Profit declined 19.3% YoY to ₹16.6 cr as operating expenses, particularly fees to hospitals (up 164% YoY), and finance costs rose significantly. The board approved a preferential issue of 16.21 lakh warrants to promoters at a minimum price of ₹565, representing a ~5% capital infusion relative to market cap. Additionally, the company is contesting a significant ₹62.7 cr income tax demand across multiple assessment years.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results, announced a promoter-led fundraise via warrants, and provided a detailed update on pending tax litigation.
Why it mattersWhile revenue growth remains robust due to the PPP model expansion, the sharp decline in profitability and the large tax demand create near-term uncertainty. The promoter warrant issue at ₹565 (above current market price of ₹556.8) signals management confidence.
Revenue (Q1 FY27): ₹235.53 crNet Profit (Q1 FY27): ₹16.55 crTax Demand under Appeal: ₹62.69 crWarrant Issue Min. Price: ₹565Fees to Hospitals (Q1): ₹40.58 crTax Demand vs TTM PAT: ~61.4%
📅 Short termThe stock may face pressure due to the 19% profit decline and the quantification of the ₹62.7 cr tax demand, though the promoter warrant pricing may provide some support.
📈 Long termStructural growth depends on the successful transition to a higher retail revenue mix (target 20% by FY27) and resolving stretched receivables from government contracts.
⚠ Risk flags
- Significant tax litigation (₹62.69 cr)
- Margin compression due to rising hospital fees
- Stretched receivables from government entities
Key Highlights
Revenue from operations grew 22.1% YoY to ₹235.53 cr in Q1 FY27.
Net Profit fell 19.3% YoY to ₹16.55 cr compared to ₹20.52 cr in the year-ago quarter.
Board approved 16,21,000 share warrants to promoters at a minimum price of ₹565 per share.
Income tax demand of ₹62.69 cr is currently under appeal before tax authorities.
Final dividend of ₹2.00 per share confirmed with a record date of September 18, 2026.
👀 What to Watch
Monitor the impact of rising hospital fees on margins and the outcome of the ₹62.7 cr tax appeal, which represents over 60% of TTM PAT. Watch for the utilization of warrant proceeds for the planned Rajasthan and Maharashtra expansions.
KRSNAA Q1 Revenue Up 22% to ₹235.5 Cr; Promoters to Infuse Capital via 16.21 Lakh Warrants
Krsnaa Diagnostics reported a strong 22.1% YoY revenue growth in Q1 FY27, reaching ₹235.53 Cr, driven by its expanding PPP footprint. However, net profit declined by 19.3% YoY to ₹16.55 Cr, primarily due to a 135% surge in finance costs and a significant increase in fees paid to hospitals. The board approved a preferential issuance of 16.21 lakh warrants to promoters at a minimum price of ₹565, which is a premium to the current market price of ₹556.8. Additionally, the company is contesting a material income tax demand of ₹62.69 Cr, representing approximately 61% of its TTM net profit.
Confidence: HIGH
What changedThe company has transitioned into a higher-cost phase with increased debt servicing and hospital fees, while promoters have signaled confidence by committing to a warrant-based fundraise at a premium to the current price.
Why it mattersWhile top-line growth remains robust due to government contracts, the bottom-line pressure and tax litigation are significant near-term risks for a mid-cap healthcare player.
Q1 Revenue: ₹235.53 CrQ1 Net Profit: ₹16.55 CrTax Demand vs TTM PAT: 61.5%Warrant Floor Price: ₹565Finance Costs (Q1): ₹14.83 CrDividend per share: ₹2.00
📅 Short termThe stock may face pressure due to the profit decline and the disclosure of the large tax demand, though the promoter warrant pricing may provide some support.
📈 Long termLong-term value depends on the successful operationalization of the Rajasthan contract and the ability to scale the retail segment to 20% of revenue to offset PPP margin pressures.
⚠ Risk flags
- Material tax demand of ₹62.69 Cr
- Significant increase in finance costs (up 135% YoY)
- High receivables risk from government health departments
Key Highlights
Revenue from operations grew 22.1% YoY to ₹235.53 Cr from ₹192.98 Cr in the previous year's quarter.
Net profit for the quarter fell to ₹16.55 Cr vs ₹20.52 Cr YoY, impacted by finance costs rising to ₹14.83 Cr.
Preferential issue of 16.21 lakh warrants to promoters approved at a floor price of ₹565 per warrant.
Income tax demand of ₹62.69 Cr (₹626.90 million) currently under appeal before tax authorities.
Final dividend of ₹2.00 per share confirmed with a record date of September 18, 2026.
👀 What to Watch
Monitor the impact of rising operational costs (hospital fees) on margins and track the legal outcome of the ₹62.69 Cr tax demand, which is a significant contingent liability.
KRSNAA expands Himachal footprint with 34 CT Scan centers under new 7-year PPP agreement
Krsnaa Diagnostics has significantly scaled its operations in Himachal Pradesh, increasing its scope from 12 to 34 CT Scan centers under a new Public Private Partnership (PPP) agreement. The contract is for an initial 7-year term, extendable by 3 years, and will operate on a majority cash basis. This expansion adds 22 new centers to the company's existing radiology network of 186 CT/MRI centers, representing a ~12% increase in total radiology capacity. The shift to a 'cash basis' model is particularly notable given the company's historical challenges with stretched government receivables in this state.
Confidence: HIGH
What changedKrsnaa has transitioned from a 12-center arrangement to a much larger 34-center long-term contract in Himachal Pradesh, nearly tripling its presence in the state.
Why it mattersHimachal Pradesh is a key revenue contributor where receivables were previously stretched; scaling up on a cash basis secures long-term revenue visibility while potentially improving the company's working capital cycle.
New Center Count: 34Incremental Centers: 22Contract Tenure: 7 yearsCapacity Increase (vs 186 existing): ~11.8%TTM Revenue: ₹773 Cr
📅 Short termThe announcement is likely to be viewed positively by the market as it demonstrates contract stickiness and significant scale-up in a core geography.
📈 Long termThis provides a decade of revenue visibility for the radiology segment and validates the company's ability to renew and expand government tenders despite operational challenges.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risks in hilly terrain
- Historical stretched receivables from government entities
- Dependency on global OEMs for equipment maintenance
Key Highlights
Scope of CT Scan diagnostic facilities increased from 12 to 34 Government Health Institutions in Himachal Pradesh
Agreement signed for an initial period of 7 years, with a 3-year extension option
Project to be implemented on a majority cash basis to improve liquidity
Represents a ~12% increase in the company's total CT/MRI center count (currently 186)
Contract renewal and scale-up reinforces Krsnaa's dominant position in the Indian PPP diagnostic segment
👀 What to Watch
Investors should monitor the execution timeline for the 22 additional centers and observe if the 'cash basis' clause effectively reduces the days sales outstanding (DSO) for the Himachal Pradesh cluster in upcoming quarterly results.
ICRA Reaffirms [ICRA]A (Stable) Rating for Rs 304.15 Cr Bank Facilities
ICRA has reaffirmed Krsnaa Diagnostics' long-term rating at [ICRA]A with a Stable outlook and its short-term rating at [ICRA]A1. The total rated bank facilities amount to Rs 304.15 crore, which includes Rs 166.60 crore in long-term and Rs 137.55 crore in short-term limits. This rated amount represents approximately 57% of the company's total debt of Rs 531 crore. The rating action includes assignments for enhanced amounts, indicating the company is securing higher credit limits to support its expansion in Rajasthan and Maharashtra.
Confidence: HIGH
What changedICRA has reaffirmed the company's credit ratings while extending the coverage to an increased total facility amount of Rs 304.15 crore.
Why it mattersMaintaining an 'A' rating ensures the company can continue to access debt at competitive rates, which is vital for its capital-intensive business model of setting up diagnostic centers under government tenders.
Total Rated Amount: Rs 304.15 CrLong-term Rating: [ICRA]A (Stable)Short-term Rating: [ICRA]A1Rated Debt vs Total Debt: ~57%Total Debt: Rs 531 Cr
📅 Short termThe reaffirmation provides stability and confirms that the company's credit profile remains healthy despite recent stock price pressure.
📈 Long termThe enhanced limits for bank guarantees support the company's long-term strategy of aggressive expansion in the PPP segment across new states.
⚠ Risk flags
- High concentration of receivables from government health departments
- Stretched receivables in Himachal Pradesh and Karnataka
Key Highlights
Total bank facilities rated by ICRA amount to Rs 304.15 crore
Long-term rating reaffirmed at [ICRA]A (Stable) for Rs 166.60 crore of fund-based limits
Short-term rating reaffirmed at [ICRA]A1 for Rs 137.55 crore of non-fund based limits (Bank Guarantees)
Rated facilities cover approximately 57% of the company's total debt of Rs 531 crore
Ratings assigned for enhanced amounts in term loans (Rs 62.15 Cr) and bank guarantees (Rs 137.55 Cr)
👀 What to Watch
Monitor the company's ability to convert the enhanced bank guarantee limits into successful PPP project executions, particularly the large Rajasthan contract which is key to FY26 growth.
Krsnaa Diagnostics Seeks Approval for Director Appointments and ₹50 Lakh Remuneration Cap
Krsnaa Diagnostics has issued a postal ballot notice to seek shareholder approval for the re-appointment of Mr. Chetan Desai for a second 5-year term and the appointment of two new Independent Directors for 2-year terms. The company is also proposing a new remuneration structure for Independent Directors, involving a commission of up to 1% of net profits, capped at a maximum of ₹50 lakhs annually starting FY 2026-27. The e-voting process is scheduled to take place between June 05 and July 04, 2026, following the cut-off date of May 29, 2026.
Key Highlights
Re-appointment of Mr. Chetan Desai as Independent Director for a 5-year term ending April 2031.
Appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors for 2-year terms.
Proposed commission for Independent Directors capped at 1% of net profits or a maximum of ₹50,00,000 per year.
E-voting period set from June 05, 2026, to July 04, 2026.
Resolutions include approval for Mr. Chetan Desai to continue directorship beyond the age of 75 years.
👀 What to Watch
Investors should review the profiles of the new director appointees and ensure the proposed commission-based remuneration is aligned with the company's long-term profitability and governance standards.
Krsnaa Diagnostics FY26 PAT Hits ₹101 Cr; Q4 PAT Surges 101% YoY with Improved Receivables
Krsnaa Diagnostics reported a resilient FY26 with total revenue of ₹7,728 million and an EBITDA of ₹2,149 million (28% margin). The company achieved a significant milestone in Q4 FY26 with PAT growing 101% YoY to ₹417 million, supported by the highest quarterly collection in its history at ₹1,580 million. Management highlighted a reduction in Days Sales Outstanding (DSO) from 155 to 139 days, addressing historical concerns regarding working capital. With a ₹5,000 million capex deployment, the company claims a long-term revenue visibility of ₹6,000 to ₹7,000 crores over the next 5-7 years.
Key Highlights
FY26 Revenue stood at ₹7,728 million with a 12% 5-year CAGR, outperforming the industry average of 8%.
Q4 PAT grew by 101% YoY to ₹417 million, while Q4 EBITDA margins remained strong at 29%.
DSO improved significantly to 139 days from 155 days in Q3, reflecting tighter working capital management.
Retail diagnostics now contributes 8% of total revenue, with a network of 3,500+ touchpoints across 5 states.
The company is deploying ₹5,000 million in capex, primarily for Rajasthan expansion and CT/MRI centers, targeting 200+ centers.
👀 What to Watch
Investors should view the improvement in DSO and record collections as a major positive for the PPP-heavy model. Monitor the scale-up of the Rajasthan project and the retail segment's progress toward double-digit contribution for margin expansion.
Krsnaa Diagnostics Q4 FY26 PAT Doubles to ₹417 Mn; Retail Revenue Surges 147% YoY
Krsnaa Diagnostics reported a steady 4% YoY revenue growth in Q4 FY26, reaching ₹1,926 million, while PAT surged 102% to ₹417 million, significantly aided by a ₹221.75 million fair valuation gain. The company's retail segment showed exceptional momentum, with revenue increasing 147% YoY to ₹158 million and its contribution to total revenue rising from 3% to 8%. For the full year FY26, revenue grew 8% to ₹7,728 million with EBITDA margins improving to 28%. The company continues to leverage its PPP infrastructure to scale its retail presence while maintaining a massive 70-95% price advantage over competitors.
Key Highlights
Q4 FY26 PAT grew 102% YoY to ₹417 million, including a ₹221.75 million fair valuation gain from investment in Apulki Healthcare.
Retail segment revenue jumped 147% YoY to ₹158 million, with patient count increasing from 0.09 million to 0.15 million.
Full-year FY26 EBITDA stood at ₹2,149 million (up 10% YoY) with margins expanding by 69 bps to 28%.
Network expanded to 190 CT/MRI centers and 4,700+ collection centers, serving 19.8 million patients in FY26.
Maintains extreme cost leadership with tests like Vitamin B12 priced at ₹69, approximately 95% lower than market competitors.
👀 What to Watch
Investors should focus on the rapid scaling of the high-margin retail segment and the execution of the Rajasthan pathology project. While the PAT jump includes one-off gains, the underlying operational efficiency and retail pivot provide a strong long-term growth narrative.
Krsnaa Diagnostics to Host Q4 & FY26 Post Earnings Conference Call on May 26, 2026
Krsnaa Diagnostics Limited has scheduled its post-earnings conference call for Tuesday, May 26, 2026, at 12:30 PM IST. The management will discuss the financial performance for the quarter and full year ended March 31, 2026. The session will include a presentation followed by an interactive Q&A for analysts and institutional investors. Transcripts and audio recordings will be published on the company's website subsequently.
Key Highlights
Conference call scheduled for May 26, 2026, at 12:30 Hrs IST.
Discussion to cover financial results for the quarter and year ended March 31, 2026.
Management will conduct an interactive Question and Answer session following the results briefing.
Audio recordings and transcripts will be accessible on the company's official website.
👀 What to Watch
Investors should monitor the call for management commentary on margin sustainability and the status of new PPP (Public-Private Partnership) project executions.
Krsnaa Diagnostics Receives Income Tax Demand Notices Totaling ₹11.31 Crore
Krsnaa Diagnostics has been served with income tax demand notices for the assessment years 2018-19 and 2019-20, amounting to a total of ₹11.31 crore including interest. These orders follow a search operation conducted by the Income Tax Department in July 2022. The company has already challenged these assessment orders before appellate and judicial forums, expressing confidence in its legal position. While the amount is currently treated as a contingent liability, the company will evaluate the need for provisioning under Ind AS 37.
Key Highlights
Total income tax demand of ₹11,30,54,699 raised for two assessment years.
Specific demands include ₹4.04 crore for AY 2018-19 and ₹7.27 crore for AY 2019-20.
The company has already initiated legal appeals and is contesting the orders on merit.
Management confirms no operational disruption despite the ongoing tax litigation.
The disclosure was delayed due to an internal compliance review after external consultants handled the initial litigation.
👀 What to Watch
Investors should monitor the outcome of the appellate proceedings as a final adverse ruling would impact the company's cash reserves and net profit. The ₹11.31 crore demand is significant but manageable for a company of this scale, provided no further liabilities arise from other assessment years.
Krsnaa Diagnostics Appoints Interim CFO and Overhauls Board with New Independent Directors
Krsnaa Diagnostics has announced a major leadership reshuffle, including the appointment of Mr. Chandra Prakash Singh as Interim CFO effective April 17, 2026. The board is adding significant expertise with new Independent Directors Raju Venkatraman (ex-Medall Healthcare) and Lilian Jessie Paul (PB Fintech board member) for two-year terms. These changes coincide with the departure of Whole-time Director Ms. Pallavi Bhatevara and two other directors as their tenures conclude in April 2026. The company has also reconstituted all major board committees, including Audit and Risk Management, to align with the new leadership structure.
Key Highlights
Mr. Chandra Prakash Singh appointed as Interim CFO effective April 17, 2026, bringing 28 years of finance and IPO experience.
New Independent Directors Raju Venkatraman and Lilian Jessie Paul join for 2-year terms starting April 25, 2026.
Whole-time Director Ms. Pallavi Bhatevara and two Independent Directors to exit upon tenure completion in April 2026.
Mr. Chetan Desai re-appointed as Independent Director for a subsequent 5-year term until April 2031.
Complete reconstitution of Audit, NRC, CSR, Stakeholders, and Risk Management committees effective April 25, 2026.
👀 What to Watch
Investors should monitor the transition to a permanent CFO and observe if the new board composition leads to any shifts in strategic direction or operational efficiency.
Krsnaa Diagnostics Overhauls Board and Appoints Interim CFO Chandra Prakash Singh
Krsnaa Diagnostics has announced a significant leadership transition, appointing two new Independent Directors, Mr. Raju Venkatraman and Ms. Lilian Jessie Paul, for two-year terms starting April 25, 2026. Simultaneously, Mr. Chandra Prakash Singh, a finance veteran with 28 years of experience, has been named Interim CFO effective April 17, 2026. The company also confirmed the re-appointment of Mr. Chetan Desai for a five-year term and the exit of three directors, including Whole-time Director Ms. Pallavi Bhatevara, upon completion of their tenures. These changes include a full reconstitution of key board committees to strengthen governance.
Key Highlights
Appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors for 2-year terms.
Mr. Chandra Prakash Singh appointed as Interim CFO, bringing 28 years of experience in finance and IPOs.
Re-appointment of Mr. Chetan Desai as Independent Director for a 5-year term until April 2031.
Cessation of three directors, including Whole-time Director Ms. Pallavi Bhatevara, effective April 2026.
Reconstitution of Audit, Risk Management, and Nomination committees effective April 25, 2026.
👀 What to Watch
Investors should monitor the transition to a permanent CFO to ensure long-term financial leadership stability. The addition of seasoned independent directors is a positive sign for corporate governance and strategic oversight.
